Compare Novavax Inc (NVAX) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Novavax Inc trades at $9.85 (market cap $1.62B), while YieldMax NVDA Option Income Strategy ETF trades at $12.62. The key difference: Novavax Inc is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| NVAX | NVDY | |
|---|---|---|
Market Cap | $1.62B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $11.19 | $17.21 |
52-Week Low | $6.22 | $11.58 |
Enterprise Value | $1.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
NVDY trades at $12.82, down 1.23% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF generates weekly dividends, recently averaging $0.10 per distribution, but faces criticism for NAV erosion despite high yields. Recent news highlights downgrades to Hold due to diminished upside participation and falling option premiums.
Outlook remains cautious; high distribution rates come at the cost of long-term capital erosion, limiting attractiveness for growth investors. Risks include dependency on Nvidia's volatility and capped upside potential. Investors prioritizing income may find value, but total return prospects are constrained.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
